Clinical Trial Update: Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 [Phase 4]

View source ↗

Summary

Phase 4 trial comparing optimized 5-FU dosing versus standard dosing in metastatic colorectal cancer treated with mFOLFOX6; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer Metastatic

Drugs mentioned

• MFOLFOX6

Snippet

Sponsor: Myriad Genetic Laboratories, Inc. | Conditions: Colorectal Cancer, Metastatic | Phase 4 | Status: TERMINATED